Ramona F. Swaby

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

29h-index5.7kcitations123works60.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(52), Head and Neck Cancer Studies(39), CAR-T cell therapy research(20), Lung Cancer Treatments and Mutations(18), Cancer Diagnosis and Treatment(18)

Publications122 total

Analysis of Plasma Epstein–Barr Virus <scp>DNA</scp> and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in <scp>KEYNOTE</scp> ‐122
Cancer Medicine·2026Open Access
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Nature Medicine·2025· 127 cited
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
BMC Cancer·2024· 10 citedOpen Access
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
Journal of Clinical Oncology·2024· 42 citedOpen Access
Abstract PO2-04-08: Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
Cancer Research·2024· 6 cited
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology·2024· 175 citedOpen Access
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
Dermatology and Therapy·2023· 2 citedOpen Access
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
Oral Oncology·2023· 11 citedOpen Access
PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
Annals of Oncology·2023Open Access
635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Abstract PO-008: Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122
Clinical Cancer Research·2023
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Journal of Clinical Oncology·2023· 13 cited
Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors
Cancer Research·2023· 2 cited
Data from Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
2023Open Access
Data from Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
2023Open Access
Supplementary Figure S1 from Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
2023Open Access
Supplementary Figure S1 from Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
2023· 1 citedOpen Access
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Annals of Oncology·2022· 100 citedOpen Access
634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 8 citedOpen Access
633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 6 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Barbara Burtness(16), Kevin J. Harrington(15), Ezra E.W. Cohen(11), Denis Soulières(11), Lisa Licitra(11), Christophe Le Tourneau(10), Burak Gümüşçü(10), Brett Hughes(9), José Dinis(7), Nicolas Mach(7), Ranee Mehra(7), Makoto Tahara(7), Danny Rischin(7), Jean‐Pascal Machiels(7), Myung‐Ju Ahn(6), Ainara Soria(6), Richard Greil(6), Gilberto de Castro(6), Nuttapong Ngamphaiboon(6), Lori J. Goldstein(6)